| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,016,736 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Behrenbruch Christian | MD & Group CEO | 2 | $996,738 | 0 | $0 | $996,738 |
| Smith Darren Charlton | Group Chief Financial Officer | 1 | $19,998 | 0 | $0 | $19,998 |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney …
Over the last 12 months, insiders at Telix Pharmaceuticals Limited have bought $1.02M and sold $0 worth of Telix Pharmaceuticals Limited stock.
On average, over the past 5 years, insiders at Telix Pharmaceuticals Limited have bought $1.02M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Behrenbruch Christian (MD & Group CEO) — $996,738. Smith Darren Charlton (Group Chief Financial Officer) — $19,998.
The last purchase of 2,071 shares for transaction amount of $19,998 was made by Smith Darren Charlton (Group Chief Financial Officer) on 2026‑09‑07.
| 2026-09-07 | Smith Darren Charlton | Group Chief Financial Officer | 2,071 0.0005% | $9.66 | $19,998 | -8.10% | ||
| 2026-04-29 | Behrenbruch Christian | MD & Group CEO | 33,435 0.0141% | $14.87 | $497,178 | +4.07% | ||
| 2026-04-28 | Behrenbruch Christian | MD & Group CEO | 34,500 0.0141% | $14.48 | $499,560 | +3.93% |
| Increased Positions | 27 | +93.1% | 528,606 | +64.22% |
| Decreased Positions | 13 | -44.83% | 230,686 | -28.02% |
| New Positions | 16 | New | 170,839 | New |
| Sold Out Positions | 4 | Sold Out | 13,008 | Sold Out |
| Total Postitions | 43 | +48.28% | 1M | +36.19% |